V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryQualified Health Claim
Compliance · The complete guide

The Qualified Health Claim: FDA Enforcement Discretion and Labeling

In short

Distinguish claim categories, assess the applicable regulatory reference, and connect scientific evidence to product-specific labeling decisions.

4,020 words · ~19 min read
Regulatory specialist reviewing a supplement label design on a tablet beside product bottles in a bright office
On this page
  1. 01What a qualified health claim is
  2. 02Qualified, authorized, and structure/function claims compared
  3. 03Map the jurisdiction, product, and authority type
  4. 04Regulation petitions and letter-specific claim review
  5. 05When qualified-claim review is worth pursuing
  6. 06Move from proposed wording to a controlled label version
  7. 07Build a traceable claim and evidence record
  8. 08Worked cases: missing qualifications, changed context, new evidence
  9. 09Connect product, artwork, and publishing records
  10. 10Common failure modes and the controls that address them
  11. 11Final review checklist for a claim-bearing label
On this page · 11 sections
  1. 1What a qualified health claim is
  2. 2Qualified, authorized, and structure/function claims compared
  3. 3Map the jurisdiction, product, and authority type
  4. 4Regulation petitions and letter-specific claim review
  5. 5When qualified-claim review is worth pursuing
  6. 6Move from proposed wording to a controlled label version
  7. 7Build a traceable claim and evidence record
  8. 8Worked cases: missing qualifications, changed context, new evidence
  9. 9Connect product, artwork, and publishing records
  10. 10Common failure modes and the controls that address them
  11. 11Final review checklist for a claim-bearing label
AI · Explain it for MY operation

How does Qualified Health Claim apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01What a qualified health claim is

A qualified health claim is, in labeling practice, a food or dietary-supplement claim that relates a substance to disease risk while qualifying the strength of the supporting scientific evidence.

For US foods, including dietary supplements, 21 CFR 101.14(a)(1) defines a health claim in terms of a relationship between a substance and a disease or health-related condition. The practical distinction in a qualified health claim is the qualification of the evidence supporting that relationship—not simply a less confident writing style.

For US conventional foods and dietary supplements, check the applicable FDA enforcement-discretion letter for the wording, product scope, and conditions relevant to the proposed qualified health claim. Keep that letter-specific assessment separate from regulation-based authorization; do not describe the qualified claim as authorized under 21 CFR 101.14.

As a practical labeling-review approach, assess the proposed relationship, qualification, product, and presentation together. The question is whether those elements fit—not merely whether the sentence sounds cautious. A useful starting point for claims substantiation is to identify the substance, the disease-risk relationship, and the scientific uncertainty the qualification communicates.

Then consider the complete consumer-facing presentation rather than reviewing the qualifying sentence in isolation. This keeps the scientific assessment and the labeling decision connected while preserving the distinction between evidence qualification and regulatory authorization. It is a review method, not a conclusion that any particular wording or product has FDA acceptance.

02Qualified, authorized, and structure/function claims compared

These categories are not interchangeable levels of promotional strength. They describe different relationships and review routes. A useful comparison asks what the wording communicates, which reference governs the review, and whether that reference fits the product. The table below is a practical review aid, not a product-specific legal determination.

Claim categoryRelationship describedReference to examineCentral review question
Qualified health claimSubstance–disease or health-related-condition relationship, with qualifying languageRelevant FDA enforcement discretion letter: examine its specific wording and scopeDoes the proposed wording preserve the qualification, and does the product fit the letter-specific scope?
Regulation-authorized health claimSubstance–disease or health-related-condition relationshipApplicable US food health-claim regulationDoes the proposed message and product fit the applicable regulation?
Dietary-supplement structure/function statementNutrient or dietary ingredient’s role in human structure or functionUS dietary-supplement provisions discussed belowDoes the message describe structure or function without crossing the disease-claim boundary?
Disease-treatment statementProduct or ingredient presented as treating diseaseProduct-specific classification assessmentDoes the intended treatment message call for a different regulatory classification?

For US foods, including dietary supplements, the relationship element of the health-claim definition in 21 CFR 101.14(a)(1) concerns a substance and a disease or health-related condition. For US food and dietary-supplement health claims, 21 CFR 101.14(c) uses significant scientific agreement among qualified experts as the scientific-support criterion for FDA authorization by regulation.

For US dietary supplements, 21 CFR 101.93(f) describes statements about a nutrient or dietary ingredient’s role in human structure or function. That US dietary-supplement permission is conditional on the statements not being disease claims under paragraph (g). This identifies a boundary, not a complete compliance checklist; the structure/function claim comparison addresses that category separately.

In practical review, treat disease-treatment wording as a separate classification issue, not a stronger qualified health claim. Likewise, keep the scientific assessment in claims substantiation distinct from the decision about the applicable review route. A reviewer should be able to explain both why the evidence supports the proposed message and why the selected category fits it. Neither answer substitutes for the other.

03Map the jurisdiction, product, and authority type

This US food-labeling discussion covers conventional foods and dietary supplements, the forms distinguished in 21 CFR 101.14(e). Start each review by identifying the destination market and product category; a shared ingredient or similar label message is not a sufficient basis for transferring a classification.

Market and productReference familyAssessment boundary
US conventional foodFood health-claim provisions; relevant FDA materialsAssess the food and proposed wording; do not import the supplement-specific structure/function discussion.
US dietary supplementFood health-claim provisions; supplement statement provisionsKeep the structure/function analysis within the supplement context covered above.
Other US product categoriesCategory-specific assessmentDrugs, devices, and nonfood chemicals are outside this article’s claim-classification scope.
Other destination marketsLocal claim and labeling frameworkConduct a separate local assessment rather than carrying the US conclusion across borders.

For US dietary supplements, the structure/function discussion remains tied to 21 CFR 101.93(f), as covered in the comparison. For adjacent classification questions, consult the medical food and FSMP boundary; for a destination-specific review, see UK supplement advertising claims.

As recommended review practice, classify authority explicitly: binding CFR provisions, official guidance, and FDA enforcement-discretion letters belong in separate record categories. Record guidance separately from the letter relevant to a qualified-claim review; do not label either as a regulation authorizing the claim. Keep internal review gates identified as recommended industry practice, not agency requirements. Software may serve as a recordkeeping or routing tool, but substantive interpretation, approval, and release remain human decisions.

04Regulation petitions and letter-specific claim review

For US food and dietary-supplement health claims, 21 CFR 101.70(a) allows any interested person to petition FDA to issue a regulation regarding a health claim. That is the agency action addressed by this regulation-petition discussion; keep it separate from the letter-scope check covered above.

What the petition provisions address

For US food and dietary-supplement health-claim petitions, 21 CFR 101.70(f), petition format B requires the scientific summary to state the public-health benefit expected from use of the proposed claim.

For US food and dietary-supplement health-claim petitions, 21 CFR 101.70(h) requires a statement signed by the person responsible for the petition. For these US petitions, the statement addresses whether, to that person's knowledge, the submission is representative and balanced, including unfavorable and favorable information known to be pertinent to evaluating the proposed claim.

Keep project milestones distinct

As an internal review practice, separate these milestones rather than using a single approval status:

  • Scientific material assembled: the evidence package is ready for assessment, not a labeling decision.
  • Agency action requested: record the action sought and the wording submitted.
  • Correspondence received: record what the communication actually addresses and route it for interpretation.
  • Product label approved internally: record the human decision for the particular wording and product version.

Link the scientific package to the claims-substantiation record, but retain separate submission, correspondence, and label-decision records. This makes project status more precise: evidence readiness, an agency request, and an internal labeling decision answer different questions.

When planning qualified-claim review, do not copy regulation-petition deadlines, outcomes, or filing mechanics into the project plan as though they establish the qualified-claim procedure. Use the separate letter-scope review described above to frame the product-specific decision.

05When qualified-claim review is worth pursuing

For a proposed US food-labeling project, begin with the intended consumer message: a substance–disease relationship, ordinary structure/function support, or another statement. Use the comparison above to select the review route before investing in artwork. The following is an internal feasibility screen, not an FDA eligibility test.

Review questionInformation neededInternal disposition
Is the proposed message ready for detailed assessment?Intended consumer takeaway, candidate wording, and a separate scientific evidence assessment.Continue assessment
Can the communication preserve an understandable qualification?Full wording in realistic label layouts and intended channel previews.Revise the communication concept
Can applicable enforcement-discretion letter scope be resolved for this product?Actual ingredient identity, product format, intended population, proposed wording, and unresolved differences.Escalate unresolved scope
Does the proposed version still omit or obscure the qualification?Final-size artwork and channel rendering showing the message as consumers would encounter it.Do not publish the proposed version.

A commercial desire for a disease-risk message is not scientific support. Evaluate the communication objective and evidence assessment separately: one describes the business aim; the other examines what the research supports. Do not treat a favorable commercial assessment as resolving scientific uncertainty.

Assess readability in the available space without inventing a statutory type-size rule. If the qualification becomes difficult to understand in a small label or channel preview, revise the concept rather than compressing away its meaning. Continuing assessment means assigning unresolved questions to human reviewers—not approving publication.

06Move from proposed wording to a controlled label version

Use a documented internal review lifecycle to connect proposed wording to a specific product and publication decision. The following workflow is recommended manufacturing practice, not a universal legal procedure.

  1. Capture the proposal before editing. Record the claim exactly as proposed, including its qualification, intended channel, responsible business owner, and affected product versions. Identify whether the request concerns packaging, a product page, or another presentation. This prevents reviewers from assessing wording without knowing where and how it will appear.
  2. Assign distinguishable review decisions. Scientific review interprets the evidence and uncertainty; regulatory review classifies the proposed claim and assesses the reference relied upon; product review checks applicability to the actual formulation; artwork review checks execution. Smaller organizations may combine responsibilities, but should record each decision separately rather than use an unexplained blanket approval.
  3. Connect the assessment to the product. Link the reference assessment to ingredient identity, formulation revision, and intended serving basis. Explain any assumptions affecting applicability. Then associate that assessment with the exact label revision submitted for review, so an accepted rationale cannot silently carry over to a different product.
  4. Review the complete presentation. Examine nearby text, visuals, placement, and how the qualification appears in the intended channel. Return changes to the relevant reviewer rather than treating layout edits as purely cosmetic. Keep the reviewed proof attached to the decision.
  5. Record the human decision. Capture the reviewer, rationale, reviewed versions, unresolved questions, and any internal conditions on publication. Assign owners to open questions and identify which prevent publication. Keep claim-wording approval separate from artwork approval and product disposition; a labeling decision is not batch release. Maintain the distinction between a label claim and a release limit.
  6. Reopen review when the basis changes. Route revised wording, reformulation, different ingredient identity, a changed intended audience, new scientific information, or changes to the reference relied upon through change control. Identify affected label versions and channels, assign the necessary reassessments, and document whether existing publication approval remains applicable before issuing replacement artwork.
From proposed claim to reviewed label
  1. 1
    ClassifyIdentify the relationship, destination market, and product category.
  2. 2
    Check scopeAssess the applicable reference against the proposed wording.
  3. 3
    Assess evidenceEvaluate relevance, limitations, and the scientific rationale.
  4. 4
    Match ProductConnect the assessment to the actual formulation revision.
  5. 5
    Review presentationExamine qualification, surrounding copy, visuals, and rendered artwork.
  6. 6
    Approve versionRecord the human decision and exact reviewed versions.
  7. 7
    Monitor changesRoute relevant changes back to the appropriate reviewer.
A recommended internal workflow with human decisions at each substantive gate.

07Build a traceable claim and evidence record

A practical evidence model should let a reviewer reconstruct why particular wording was accepted for a particular product version. The following record structure is a design recommendation, not a set of prescribed regulatory database fields.

Store the exact claim and qualification text in dedicated fields, separate from summaries, promotional paraphrases, and reviewer comments. Give each wording version a stable identifier and link it to separate records:

  • Regulatory reference: identify the document, authority type, applicable passage, date, and retained version. Keep a letter distinct from a regulation or guidance document.
  • Scientific assessment: capture study population, exposure or intake basis, endpoint, relevance to the proposed relationship, limitations, and unfavorable findings. Explain applicability; a citation alone does not establish that the study supports this wording for this product.
  • Product applicability: identify the specific ingredient rather than only its broad ingredient family. Link the formulation revision and relevant specifications, not merely the marketing product name. Keep the distinction between a label claim and a release limit explicit.
  • Label asset: identify the artwork revision, packaging format, and location of the claim and qualification so the decision connects to the actual presentation.
  • Human decision: record the reviewer, decision date, rationale, conditions, and exact reference, assessment, product, wording, and artwork versions reviewed.

Record units alongside quantitative evidence and specifications. Preserve the original basis—per serving, daily intake, or concentration—and document any conversion separately with its assumptions. Make current and superseded versions distinguishable without overwriting the historical decision links; an audit trail review workflow can help structure review of changes.

This model is portable across document-controlled processes and suitable information systems, without implying a particular software architecture. Smaller teams can maintain the same fields in a spreadsheet or quality-management module as long as each record remains individually retrievable and attributable.

Linked Claim-Review Records

Claim

Exact wording and qualification.

  • claim_id
  • claim_type
  • claim_text
  • qualification_text
  • claim_version

Regulatory Reference

Authority type and scope.

  • reference_id
  • reference_type
  • official_url
  • jurisdiction
  • product_scope

Scientific Evidence

Relevance and contrary findings.

  • evidence_id
  • study_reference
  • population
  • endpoint
  • unfavorable_findings

Product

Assessed formulation and audience.

  • product_id
  • formulation_version
  • ingredient_identity
  • serving_basis
  • intended_population

Label Asset

Version-specific published presentation.

  • asset_id
  • claim_id
  • channel
  • locale
  • artwork_version

Review decision

Human judgment and rationale.

  • decision_id
  • reviewer_id
  • reviewed_version
  • decision
  • decision_rationale
Suggested records connect wording, evidence, product scope, and accountable decisions.

08Worked cases: missing qualifications, changed context, new evidence

These hypothetical cases illustrate internal review decisions, not regulatory acceptance or predicted FDA outcomes. Each assumes a US food or dietary-supplement labeling project. The decisions are qualitative; no dose, concentration, or nutrient-limit calculations are involved.

Conventional food: qualification lost during export

Assumption: internal review has accepted a particular claim-and-qualification combination for a specified product revision. Discrepancy: the exported artwork retains the main statement but drops part of the qualification.

The reviewer compares the approved text with the rendered asset, identifies the omission, and stops publication of that asset. The artwork owner restores the missing wording and checks the corrected rendering—not just the editable text file—before a new version-specific review and sign-off.

Dietary supplement: surrounding material changes the message

Assumption: a previously reviewed structure/function sentence is reused in a new layout. Discrepancy: adjacent imagery and surrounding text introduce a disease implication that was absent from the earlier presentation.

For US dietary-supplement labeling, 21 CFR 101.93(g)(2) states that FDA considers the presentation’s context when determining whether a statement is a disease claim. Applying that contextual principle, the reviewer assesses the entire presentation rather than approving the sentence in isolation, escalates the classification question to the responsible regulatory reviewer, and holds publication pending a decision.

New evidence: revisit the scientific rationale

Assumption: a newly assessed study raises a relevant limitation for an existing claim assessment. Discrepancy: the current rationale does not address that limitation.

The scientific reviewer traces the affected claim records to product revisions and artwork, then evaluates whether the finding changes the earlier rationale. Through change control, responsible reviewers document continued use, revision, or withdrawal of the affected wording—a reassessment of basis, distinct from the export correction above, which restores an already reviewed presentation.

09Connect product, artwork, and publishing records

For qualified-health-claim labeling, a practical integration design connects the reviewed product configuration to the exact wording and asset sent downstream. The following are vendor-neutral implementation options, not statements of existing software capabilities or regulatory requirements.

  • Product master to evidence repository: pass stable product and claim identifiers with the formulation revision and evidence-record version. A matching product name does not establish that the reviewed formulation matches the published asset; use the recipe supersession history to resolve formulation changes.
  • Evidence repository to document control: associate the reviewed claim text with its evidence references and human approval record, preserving the versions used in that decision.
  • Document control to artwork management: transfer the controlled wording revision and link it to the artwork revision incorporating it.
  • Artwork management to publishing channels: send the designated asset version and retain destination identifiers, receipt status, and confirmation of the version actually displayed or distributed.

Transfer success is not review success: a file can arrive intact while containing obsolete wording. Keep human approval separate from transport, synchronization, and publication status.

For failed transfers or version mismatches, preserve the last reviewed version without assuming it remains suitable for publication. Identify affected destinations, reconcile the mismatch, and record downstream confirmation before closing the exception, using a controlled manual fallback where needed.

10Common failure modes and the controls that address them

The controls below are recommended labeling practice, not universal legal procedures. Each pairs a detectable error with a review step and a recovery record.

FailureObservable signalPreventive controlRecovery record
Qualification separated from the main statementRendered asset omits or disconnects qualifying wording.Compare the rendered proof with accepted wording and layout.Corrected asset, proof comparison, and reviewer sign-off.
Product applicability assumed from an ingredient nameRationale names the ingredient but not the product version.Link applicability review to the formulation version and scientific relevance assessment.Revised assessment identifying product differences and disposition.
Superseded artwork publishedPublished asset differs from the approved version identifier.Match publishing references to approved artwork before publication.Replacement confirmation and affected-channel inventory.
Review status mistaken for agency statusA generic approved field obscures who decided what.Separate scientific review complete, artwork approved, and agency correspondence logged.Corrected status, decision owner, and supporting correspondence.
Surrounding context changes the claim's meaningAdjacent copy or visuals differ from the reviewed proof.Review the complete rendered presentation after contextual changes.Context comparison and documented classification reassessment.

The contextual rule behind the last row—21 CFR 101.93(g)(2), discussed in the worked supplement case above—means sentence-only review can miss a problem introduced by adjacent copy or visuals. Train reviewers to re-examine the full rendered page whenever layout, imagery, or nearby marketing copy changes, even when the claim sentence itself is untouched.

Keep recovery proportionate: correcting an asset, reassessing scientific relevance, and reconsidering classification are different tasks. Route asset corrections through packaging and labeling controls. Use an explicit signature meaning statement to identify what a human reviewer accepted. Close the recovery record with the affected version, decision rationale, and confirmation that the intended correction reached its destination.

11Final review checklist for a claim-bearing label

Use these gates as a recommended internal acceptance control, not a statutory procedure. Each gate should point to a completed, attributable decision and an identifiable record—not a checkbox stating that compliance was checked. Assign named reviewers to the roles below.

Review gateRecord to examineDecision owner
Market and product identifiedMarket assessment naming jurisdiction, product category, and intended audienceRegulatory lead
Claim category assessedClassification memo tied to the proposed wordingRegulatory reviewer
Applicable reference identifiedReference register distinguishing regulation, guidance, and applicable agency letterRegulatory reviewer
Evidence relevance assessedSigned assessment connecting evidence to the substance, population, and proposed messageScientific reviewer
Product revision matchedFormula and specification revisions linked to the claim assessmentProduct technical owner
Complete presentation reviewedMarked artwork proof showing wording, qualification, placement, and surrounding contentLabeling reviewer
Exceptions resolvedIssue log documenting dispositions and closure evidenceDesignated approval owner
Publication version confirmedPublication manifest matching approved artwork to destination filesPublishing owner

For every unresolved question, record an explicit internal disposition: return for revision, seek specialist assessment, or withhold publication of the proposed version. Assign an owner and retain the reason; do not treat silence as acceptance. Route resulting edits through change control and examine relevant version history through an audit trail review workflow.

The final human decision should name the exact product and artwork revisions reviewed; checklist completion is neither regulatory certification nor a release decision.

Operational test: another qualified reviewer should be able to reconstruct why this wording was selected for this product and this presentation.

Frequently asked questions

Q.How should an imported food be assessed when its home-market label already carries a health claim?+

As a practical review approach, assess the proposed US label separately rather than treating home-market acceptance as the conclusion. Record the original wording, its translation, the product composition, intended audience, and the basis asserted for US use. If the supplier cites a qualified health claim, request the relevant FDA letter for a product-specific assessment. Keep foreign-market classifications, such as ANVISA or FFC, in a separate comparison record so their terminology does not substitute for US review.

Q.How can a private-label owner evaluate a supplier's claim-support package without simply adopting the supplier's conclusion?+

A useful independent review separates the supplier's conclusion from its supporting documents. Build a claims-substantiation matrix connecting each proposed statement to study findings, ingredient identity, formulation, intake conditions, and limitations. Ask the reviewer to explain mismatches rather than merely sign the supplier's summary. Also distinguish evidence for the health relationship from evidence that the finished product contains the stated substance; label claims and release limits address a different operational question. Record unresolved gaps and the owner's publication decision.

Q.What should a reviewer document when the study population differs from the intended label audience?+

As scientific-review practice, document the differences that could change interpretation: baseline health, nutritional status, age group, concurrent treatment, background diet, and exposure conditions. Explain whether each difference weakens applicability, introduces uncertainty, or suggests a narrower audience. Distinguish directly observed findings from extrapolation, and identify additional evidence that could resolve the gap. If real-world evidence is considered, record its relevance and limitations separately. The resulting memo should support a reasoned wording decision, not simply describe participants.

Q.Does using a cautious verb such as may determine the claim category?+

No. As a review practice, do not classify a statement from its verb alone. For US foods, including dietary supplements, 21 CFR 101.14(a)(1) defines health claims by the relationship characterized between a substance and a disease or health-related condition. Review the complete statement and its context before comparing it with a structure/function claim. Record the relationship communicated, the proposed category, and the basis for that classification; cautious wording is not a substitute for that analysis.

Q.How should a multilingual review preserve the meaning of qualifying language when a direct translation does not fit?+

A practical translation review starts with a meaning specification: what benefit is described, how uncertain the evidence is, whom the statement concerns, and which conditions limit it. Ask a qualified language reviewer to compare those elements, not merely word order. If the translation does not fit, redesign the layout rather than silently shortening qualifications. Route substantive edits through change control, and retain the approved translation alongside the artwork in the packaging and labeling review record.

Q.Which information in a US food or dietary-supplement health-claim petition becomes publicly available?+

For US food and dietary-supplement health-claim petitions, 21 CFR 101.70(e) makes all petition data and information available for public disclosure once FDA issues the notice of filing, except that clinical investigation reports, adverse reaction reports, product experience reports, consumer complaints, and similar data are available only after deleting information identifying the product user or any third party such as a physician, hospital, or other institution. Separately, for US food and dietary-supplement petitions, 21 CFR 101.70(f), attachment E.2.a requires all information relied upon to support the health claim. As submission-control practice, inventory the proposed contents, identify commercially sensitive material, and preserve an audit trail of that assessment before filing.

Q.How should a disagreement between scientific and regulatory reviewers be recorded and resolved before publication?+

A useful decision record states the disputed wording, each reviewer's reasoning, the evidence or interpretation at issue, and the consequence for publication. Separate disagreement about scientific applicability from disagreement about the proposed regulatory basis. Assign an accountable decision-maker and record whether the outcome is revised wording, additional assessment, or withholding publication. Escalate unresolved issues through management review. Define each approval's scope using a clear signature meaning statement; a recorded approval should not conceal an unresolved objection.

Q.How should image-only labels, accessibility text, and abbreviated product listings be checked for lost qualifications?+

As a content-review practice, test each presentation independently: the rendered label image, alternative text, screen-reader sequence, mobile listing, and shortened retailer description. Compare the benefit statement with its qualifications in each version, including crops and truncation. Flag versions that retain the benefit but omit uncertainty or conditions. Keep screenshots and text exports with the review record, and assign an owner for corrections. This channel-specific check can inform a broader supplement claim exposure review without replacing scientific assessment.

Primary sources

  • 21 CFR 101.14
  • 21 CFR 101.70
  • 21 CFR 101.93
  • FDA: Qualified Health Claims
Software that covers Qualified Health Claim
V5 Ultimate (FDA Compliance)
V5 Ultimate is a single-platform FDA compliance system for US manufacturers regulated under 21 CFR — pharma (210/211), medical…
Talk to us about Qualified Health Claim

Want to see how Qualified Health Claim could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Inside V5
  • → Score your compliance gap — then download the validation pack.
  • → Document control — one version in force, every change signed and explained.
  • → QMS — quality records next to the work they concern.
Related terms
  • → 21 CFR Part 11
  • → EU Annex 11
  • → 21 CFR 211
  • → 21 CFR 820
  • → GAMP 5
  • → CSV
  • → CSA
  • → IQ / OQ / PQ

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC